Почетна › Гојазност › Северна Каролина

Kliničke studije za Гојазност u državi Северна Каролина

40 studija za Гојазност traži učesnike na lokacijama u državi Северна Каролина.

Gradovi u državi Северна Каролина

Zvanični tekst studije (na engleskom)

Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight

Centricity Research, Morehead City

Тражи се учесникФаза 3

Узраст од 18 до 99 · Оба пола · Ажурирано 9. 11. 2026. · NCT07871409

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Research Site, Statesville

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07776509

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Centricity Research Morehead City Multispeciality, Morehead City
Wake Forest University Health Sciences, Winston-Salem

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT07351058

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Centricity Research Morehead City Specialty, Morehead City
Accellacare of Raleigh, Raleigh
Accellacare Research of Wilmington, Wilmington

Тражи се учесникФаза 3

Узраст од 18 до 99 · Оба пола · Ажурирано 6. 11. 2026. · NCT07575399

A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity

Medication Management, LLC, Greensboro
Monroe Biomedical Research, Monroe
Accellacare - Wilmington, Wilmington

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07845500

A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1)

Novant Health Granite Quarry Internal Medicine (knee x-ray), Granite Quarry
Monroe Biomedical Research, Monroe
Accellacare - Salisbury, Salisbury
и још 2

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07919678

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Medication Management, Greensboro
Monroe Biomedical Research, Monroe
West Clinical Research, Morehead City
и још 1

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07794579

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Medication Management, LLC, Greensboro
Accellacare - Wilmington, Wilmington
Jeffrey Coleman, OD, Wilmington

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 5. 11. 2026. · NCT07595549

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Revival Research Institute, LLC, Cary
Onsite Clinical Solutions - Huntersville, Huntersville

Тражи се учесникФаза 4

Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06857942

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

PharmQuest Life Sciences, LLC, Greensboro
West Clinical Research, Morehead City
Trial Management Associates - Wilmington - Floral Parkway, Wilmington

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

University of North Carolina Medical Center, Chapel Hill
Medication Management, Greensboro
Carteret Medical Group, Morehead City
и још 1

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07392190

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Coastal Research Institute - Fayetteville, Fayetteville

Тражи се учесникФаза 3

Узраст од 18 до 70 · Оба пола · Ажурирано 4. 11. 2026. · NCT06937099

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Coastal Research Institute - Fayetteville, Fayetteville

Тражи се учесникФаза 3

Узраст од 18 до 70 · Оба пола · Ажурирано 4. 11. 2026. · NCT06937086

A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

Carolina Research Center, Shelby

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07915609

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

UNC Children's Hospital, Chapel Hill
Duke Children's Primary Care, Durham
Lucas Research, Inc, Morehead City

Тражи се учесникФаза 3

Узраст од 6 до 17 · Оба пола · Ажурирано 4. 11. 2026. · NCT06672549

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Lucas Research, Inc., Morehead City
Shelby Clinical Research, Shelby

Тражи се учесникФаза 2

Узраст од 18 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT06897475

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Research Site, Rocky Mount
Research Site, Statesville
Research Site, Wilmington

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT07784725

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Research Site, Monroe

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07784270

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Medication Management /ID# 281965, Greensboro
Monroe Biomedical Research /ID# 282009, Monroe
Centricity Research - Morehead city /ID# 283264, Morehead City
и још 2

Тражи се учесникФаза 2

Узраст од 18 до 75 · Оба пола · Ажурирано 27. 10. 2026. · NCT07752979

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

TMA Headlands, Wilmington

Тражи се учесникФаза 2

Узраст од 18 до 75 · Оба пола · Ажурирано 26. 10. 2026. · NCT07837973

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

ACCOMPLISH-2 Research Site, Charlotte
ACCOMPLISH-2 Research Site, Durham
ACCOMPLISH-2 Research Site, Fayetteville
и још 2

Тражи се учесникФаза 3Здраве особе су добродошле

Узраст од 18 до 79 · Оба пола · Ажурирано 20. 10. 2026. · NCT07654374

Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events

Monroe Biomedical Research, LLC, Monroe
PHC Accelacare, Statesville
Accellacare, Wilmington

Тражи се учесникФаза 1

Узраст 18 и старији · Оба пола · Ажурирано 19. 10. 2026. · NCT07607587

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Medication Management, Greensboro
Monroe Biomedical Research, Monroe
Lucas Research, Inc, Morehead City
и још 1

Тражи се учесникФаза 2

Узраст од 18 до 75 · Оба пола · Ажурирано 8. 10. 2026. · NCT07589608

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Medication Management, Greensboro
Monroe Biomedical Research, Monroe
Lucas Research, Inc, Morehead City
и још 1

Тражи се учесникФаза 2

Узраст од 18 до 75 · Оба пола · Ажурирано 7. 10. 2026. · NCT06143956

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Accellacare of Hickory, Hickory
Carolina Research Center Inc, Shelby

Тражи се учесникФаза 3

Узраст од 18 до 99 · Оба пола · Ажурирано 5. 10. 2026. · NCT07684235

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

West Clinical Research, Morehead City

Тражи се учесникФаза 3

Узраст од 18 до 99 · Оба пола · Ажурирано 5. 10. 2026. · NCT07684144

FAMily-centered WEight Loss for Black Adults (FAM WEL B-ing)

University of North Carolina at Chapel Hill, Chapel Hill

Тражи се учесник

Узраст од 18 до 75 · Оба пола · Ажурирано 29. 9. 2026. · NCT06724406

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Medication Mgmnt, LLC_Grnsboro, Greensboro
Accellacare of Raleigh, Raleigh
Accellacare-Salisbury PMG Res, Salisbury
и још 1

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

PharmQuest Life Sciences LLC, Greensboro
Piedmont Healthcare/Research, Statesville

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT07668414

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Monroe Biomedical Research, Monroe

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 22. 9. 2026. · NCT07321886

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

AURORA-2 Clinical Site, Charlotte
AURORA-2 Clinical Site, Durham
AURORA-2 Clinical Site, Greenville
и још 2

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743450

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

AURORA-1 Clinical Site, Charlotte
AURORA-1 Clinical Site, Greenville
AURORA-1 Clinical Site, Morehead City
и још 1

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT07743463

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

PharmQuest, Greensboro
KDCILM, LLC & Accellacare US, Inc., Wilmington

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 4. 9. 2026. · NCT07745504

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Piedmont Healthcare/Research, Statesville

Тражи се учесникФаза 3

Узраст 18 и старији · Оба пола · Ажурирано 17. 8. 2026. · NCT07509307

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

ACCOMPLISH-1 Research Site, Charlotte
ACCOMPLISH-1 Research Site, Durham
ACCOMPLISH-1 Research Site, Fayetteville
и још 3

Тражи се учесникФаза 3

Узраст од 18 до 79 · Оба пола · Ажурирано 10. 8. 2026. · NCT07654361

A Phase 2A Clinical Trial to Assess the Safety and Tolerability of ERX1000 in Men and Women for the Treatment of Obesity.

Monroe Biomedical Research, Monroe

Тражи се учесникФаза 2

Узраст од 18 до 60 · Оба пола · Ажурирано 22. 6. 2026. · NCT07570758

Pregnancy Exercise Mode Effect on Childhood Obesity

East Carolina University, Greenville

Тражи се учесникЗдраве особе су добродошле

Узраст од 18 до 45 · Жене · Ажурирано 4. 6. 2026. · NCT04805502

NDPP-NextGen: A Clinical Trial to Reduce Intergenerational Obesity and Diabetes Risks

Wake Forest University Health Sciences, Winston-Salem

Тражи се учесникЗдраве особе су добродошле

Узраст од 18 до 39 · Жене · Ажурирано 27. 2. 2026. · NCT05674799

A Mobile Intervention to Reduce Pain and Improve Health-III

Wake Forest University, Winston-Salem

Тражи се учесникФаза 2

Узраст 65 и старији · Оба пола · Ажурирано 20. 2. 2026. · NCT06623669

MAINTAIN (Mucosal AblatIoN Therapy After INcretins)

True You Weight Loss, Cary
True You Weight Loss, Cary

Тражи се учесник

Узраст од 21 до 65 · Оба пола · Ажурирано 21. 3. 2025. · NCT06734312

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.